Multimodal therapeutic strategy for pancreatic cancer: EGFR-targeted gelatin-based nanoparticles for combination wild-type p53 gene and cytotoxic drug delivery.
Pancreatic adenocarcinoma is the fourth lethal cancer in the United States. Many therapeutic strategies such as the chemotherapy and gene therapy have been applied as therapeutic reagents. However, there are still many limitations for ideal therapeutic outcome, which reflect drug resistance, ineffic...
| Published: |
|
|---|---|
| Online Access: | http://hdl.handle.net/2047/d20003307 |
| Summary: | Pancreatic adenocarcinoma is the fourth lethal cancer in the United States. Many therapeutic strategies such as the chemotherapy and gene therapy have been applied as therapeutic reagents. However, there are still many limitations for ideal therapeutic outcome, which reflect drug resistance, inefficient delivery and short residence in tumor. Urgent need exists for development of novel therapeutic strategies, which could improve the dismal survival statics for pancreatic
cancer patients. |
|---|